VIVEbiotech at the Advanced Therapies Congress 2026

VIVEbiotech is pleased to participate once again in one of the leading global gatherings in the advanced therapies field. Our team is already on site at ExCeL London, connecting with partners, innovators, and organizations committed to advancing cell and gene therapy solutions.

Representing VIVEbiotech at this year’s congress are Natalia Elizalde, Chief Business Development Officer; Miguel Álvarez, Business Development Manager; and Andrés Lamsfus, Customer Product Development Manager. Their presence underscores our ongoing commitment to collaborating with industry leaders and contributing to the scientific and strategic discussions shaping the future of advanced therapies.

As every year, this congress offers an invaluable opportunity to strengthen collaborations, exchange insights, and engage with the global community driving the development of next‑generation therapies.

If you are attending the event, we invite you to reach out through the official event platform:
👉 https://page.swapcard.com/app/terrapinn-events/

Or, if you prefer, contact us at https://www.vivebiotech.com/en/contact/ or by email at [email protected].

If you are not in London this week, you can explore the upcoming conferences where VIVEbiotech will be present throughout 2026: 👉 https://www.vivebiotech.com/en/events/

From early development to commercial manufacturing, both for ex vivo and in vivo, VIVEbiotech supports lentiviral vector programs end‑to‑end, accompanying clients through every stage of production.